These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2308 related articles for article (PubMed ID: 8206495)

  • 1. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
    Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
    Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
    [No Abstract]   [Full Text] [Related]  

  • 2. Peptide mimics of a tumor antigen induce functional cytotoxic T cells.
    Apostolopoulos V; Lofthouse SA; Popovski V; Chelvanayagam G; Sandrin MS; McKenzie IF
    Nat Biotechnol; 1998 Mar; 16(3):276-80. PubMed ID: 9528009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
    Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
    J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC-restricted T cells.
    Kourilsky P; Jaulin C; Ley V
    Semin Cancer Biol; 1991 Oct; 2(5):275-82. PubMed ID: 1773044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of melanoma antigen expression in cancer therapy.
    Gillespie AM; Coleman RE
    Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymerised autologous tumor tissue particles in experimental cancer immunotherapy with special reference to the effects on the immune system of the host.
    Syrjänen KJ; Soimakallio S
    Arch Geschwulstforsch; 1980; 50(8):724-34. PubMed ID: 6784699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor immunology.
    Stevenson HC; Tsang KY
    Immunol Ser; 1990; 50():513-33. PubMed ID: 2091767
    [No Abstract]   [Full Text] [Related]  

  • 8. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of tumor-regression antigens in melanoma.
    Kawakami Y; Robbins PF; Wang RF; Rosenberg SA
    Important Adv Oncol; 1996; ():3-21. PubMed ID: 8791125
    [No Abstract]   [Full Text] [Related]  

  • 10. [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives].
    Gaugler B; Olive D
    Pathol Biol (Paris); 1998 Dec; 46(10):771-8. PubMed ID: 9922993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genes coding for tumor-specific rejection antigens.
    Boon T; Van den Eynde B; Hirsch H; Moroni C; De Plaen E; van der Bruggen P; De Smet C; Lurquin C; Szikora JP; De Backer O
    Cold Spring Harb Symp Quant Biol; 1994; 59():617-22. PubMed ID: 7587121
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tumor rejection antigen and cancer immunotherapy].
    Matsutake T; Nakayama E
    Gan To Kagaku Ryoho; 1995 Nov; 22(13):1871-7. PubMed ID: 7487115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
    J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
    Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
    J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic tumor antigens: diagnostic markers and targets for immunotherapy.
    Finn OJ
    Important Adv Oncol; 1992; ():61-77. PubMed ID: 1374733
    [No Abstract]   [Full Text] [Related]  

  • 17. Cancer. Cancer immunotherapy is more than a numbers game.
    Offringa R
    Science; 2006 Oct; 314(5796):68-9. PubMed ID: 17023641
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of genes encoding T cell defined tum- antigens.
    Van Pel A; De Plaen E; Lurquin C; Van den Eynde B; Lethé B; Hainaut P; Lemoine C; Boon T
    Princess Takamatsu Symp; 1988; 19():255-63. PubMed ID: 3151988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rejection antigens of tumors and specific immunotherapy of cancer].
    Boon T; Lucas S
    Bull Mem Acad R Med Belg; 1996; 151(12):469-79. PubMed ID: 9491625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
    Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
    Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 116.